Clinical Trial Update: A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION

View source ↗

Summary

A completed clinical trial evaluating whether PDE5 inhibitors influence the onset of acute non-arteritic ischemic optic neuropathy (NAION).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ischemic Optic Neuropathy
• Optic Neuropathy

Drugs mentioned

• PDE5 inhibitors

Snippet

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Conditions: Optic Neuropathy, Ischemic | Status: COMPLETED | Results posted: 2013-10-17